Skip to main content
. 2007;9(Suppl 2):S13–S18.

Table 2.

Results of Docetaxel Trials for Hormone-Refractory Prostate Cancer: SWOG 9916 and TAX 327

SWOG 9916 TAX 327
Medications Docetaxel/estramustine Docetaxel q3wk/
Prednisone
Median OS (vs M/P) 17.5 mo (15.6 mo) 18.9 mo (16.5 mo)
Hazard ratio (vs M/P) 0.8 0.76
PSA response (vs M/P) 50% (27%) 45% (32%)
Neutropenic fever 5% 3%

M/P, mitoxantrone and prednisone; OS, overall survival.